Modified low density lipoproteins differentially bind and activate the C1 complex of complement.
Several studies suggest that complement plays an important role in atherogenesis. To further investigate this question, we have studied the ability of native and modified forms of low density lipoprotein (LDL) to bind and activate C1, the complex that triggers the classical pathway of complement. For this purpose, LDL was both obtained commercially and purified according to an established procedure, and oxidized (oxLDL) and enzymatically modified (E-LDL) derivatives were generated from each preparation. Whereas the unmodified LDL and oxLDL samples did not activate C1 in the presence of excess C1 inhibitor, the E-LDL derivatives obtained by sequential treatment of LDL with a protease and then with cholesterol esterase triggered efficient C1 activation under these conditions, with activation levels approximately 60% upon incubation with 1 microM E-LDL for 90 min at 37 degrees C. In agreement with these findings, as shown by surface plasmon resonance spectroscopy (SPR), the C1q recognition subunit of C1 showed no interaction with unmodified LDL but bound to both E-LDL samples with high affinity (K(D)=58-75 nM). More unexpectedly, although they did not trigger direct C1 activation, both oxLDL samples were also efficiently recognized by C1q. Whereas the oxLDL derivative of commercial LDL activated C1 to a significant extent ( approximately 30%) in the presence of C-reactive protein (CRP), much lower activation levels (<10%) were obtained using the oxLDL derivative of purified LDL. As measured by SPR, CRP bound equally well to the oxLDL and E-LDL derivatives obtained from purified LDL. These data provide the first experimental evidence that E-LDL triggers efficient C1 activation under conditions close to the physiological situation, suggesting that activation of the classical complement pathway by this derivative may be a crucial factor in the pathogenesis of atherosclerosis. In contrast, it appears unlikely that oxLDL significantly activates C1 directly or in a CRP-dependent manner in vivo.
Biró
Adrienn
A
IIIrd Department of Medicine, Research Laboratory, Semmelweis University, Budapest, Hungary.
Thielens
Nicole M
NM
Cervenák
László
L
Prohászka
Zoltán
Z
Füst
George
G
Arlaud
Gérard J
GJ
D000818:Animals; D050197:Atherosclerosis / Q000276:immunology / Q000378:metabolism; D002417:Cattle; D003172:Complement C1 / Q000378:metabolism*; D003171:Complement Pathway, Classical / Q000276:immunology*; D006801:Humans; D008077:Lipoproteins, LDL / Q000378:metabolism* / Q000502:physiology; D011485:Protein Binding / Q000276:immunology
D003172:Complement C1; D008077:Lipoproteins, LDL